Pharmacy World and Science

, Volume 24, Issue 4, pp 162–165 | Cite as

Anti-asthmatic drugs dosage forms in children: a cross-sectional study

  • Eric Schirm
  • Hilde Tobi
  • Henkjan Gebben
  • Lolkje T.W. de Jong-van den BergEmail author


Objective: To describe the choice of drugs as well as the dosage forms of anti-asthmatic drugs in children with regard to different age groups.Methods: Cross-sectional study based on computerized pharmacy dispensing records of 1999 for children aged 0–16 years in the north of the Netherlands. All children were selected and divided in the following age groups: 0–1, 2–5, 6–11 and 12–16-year-olds.Results: Inhaled beta2-agonists and inhaled corticosteroids were the most widely used anti-asthmatic drugs in all age groups (respectively 59 and 58 users per 100 anti-asthmatic using 0–16 year-olds). Cromones were rarely used. Up to four years of age the use of treatment with aerosol inhalers increased simultaneously with a decrease of oral dosage forms. The use of dry powder inhalers started at the age of approximately 4 years old and increased to about 85% of the users at the age of 11, with the strongest increase around the age of 6 and 7.Conclusion: The choice of drugs and dosage forms corresponds with what might be expected based on guidelines for the treatment of asthma in children, except for the high use of deptropine in the youngest age group. Anti-asthmatic drugs for preventive treatment are used so frequently without beta2-agonists that questions about possible overtreatment need to be raised.

Anti-asthmatics Asthma Child Dosage forms Drug-utilization study Pediatrics Pharmacoepidemiology Pharmacy records 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schirm E, Van den Berg PB, Gebben HJ, Sauer PJJ, De Jongvan den Berg LTW. Drug use of children in the community assessed through pharmacy dispensing data. Br J Clin Pharmacol 2000;50(5):473-8.PubMedGoogle Scholar
  2. 2.
    Warner JO. Review of prescribed treatment for children with asthma in 1990. BMJ 1995; 311:663-6.PubMedGoogle Scholar
  3. 3.
    Warner JO, Naspitz CK. Third international pediatric consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr Pulmonol 1998; 25:1-17.PubMedGoogle Scholar
  4. 4.
    De Jong-van den Berg LTW, Feenstra N, Toft Sorensen H, Cornel MC, EuroMAP group. Improvement of drug exposure data in a registration of congenital anomalies. Pilot study: pharmacist and mother as sources for drug exposure data during pregnancy. Teratology 1999; 60:33-6.PubMedGoogle Scholar
  5. 5.
    Lau HS, De Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50:619-25.CrossRefPubMedGoogle Scholar
  6. 6.
    Tobi H, Van den Berg PB, De Jong-van den Berg LTW. The InterAction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E (eds) Medical data analysis. Lect Notes Comput Sci 2000;1933:206-11.Google Scholar
  7. 7.
    Schirm E, Gebben HJ, Tobi H, De Jong-van den Berg LWT. Nog steeds deptropinevoorschriften voor 0-4-jarigen [Deptropine still prescribed for the 0-4-year-old]. Ned Tijdschr Geneeskd 2000;144:2409-11.PubMedGoogle Scholar
  8. 8.
    Dirksen WJ, Geijer RMM, De Haan M, De Koning G, Flikweert S, Kolnaar BGM. NHG-standaard asthma bij kinderen (eerste herziening) [The standard of the Dutch Society of General Physicians on asthma in children (first revision)]. Huisarts Wet 1998;41:130-43.Google Scholar
  9. 9.
    Pedersen S. Inspiratory capacity through the Turbuhaler in various patient groups. J Aerosol Med 1994;7:S55-8.PubMedGoogle Scholar
  10. 10.
    Agertoft L, Pedersen S. Importance of training for correct Turbuhaler use in preschool children. Acta Paediatr 1998:87:842-7.PubMedGoogle Scholar
  11. 11.
    Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 1999;159:941-55.PubMedGoogle Scholar
  12. 12.
    Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000;106:e8.PubMedGoogle Scholar
  13. 13.
    Jepson G, Butler T, Gregory D, Jones K. Prescribing patterns for asthma by general practitioners in six European countries. Respir Med 2000;94:578-83.PubMedGoogle Scholar
  14. 14.
    Lagerløv P, Veninga CMM, Muskova M, Hummers-Pradier E, Stålsby Lundborg C, Andrew M, Haaijer-Ruskamp FM, on behalf of the Drug Education (DEP) group. Asthma management in five European countries: doctors' knowledge, attitudes and prescribing behaviour. Eur Respir J 2000;15:25-9.PubMedGoogle Scholar
  15. 15.
    Paterson NA, Peat JK, Mellis CM, Xuan W, Woolcock AJ. Accuracy of asthma treatment in schoolchildren in NSW, Australia. Eur Respir J 1997;10:658-64.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Eric Schirm
    • 1
  • Hilde Tobi
    • 1
  • Henkjan Gebben
    • 2
    • 3
  • Lolkje T.W. de Jong-van den Berg
    • 2
    • 4
    Email author
  1. 1.Department of Social Pharmacy and PharmacoepidemiologyGroningen University Institute for Drug Exploration (GUIDE)GroningenThe Netherland
  2. 2.InterAction Working GroupNorthern NetherlandsThe Netherlands
  3. 3.Lewenborg PharmacyGroningenThe Netherlands
  4. 4.Department of Social Pharmacy and PharmacoepidemiologyGroningen University Institute for Drug ExplorationGroningenThe Netherlands

Personalised recommendations